spec sheet11 rows
Vosoritide (brand name Voxzogo) is a lab-made version of C-type natriuretic peptide (CNP, a natural molecule that helps regulate bone growth). It is approved to help children with achondroplasia (the most common form of dwarfism) grow taller by targeting the overactive growth signal behind the condition. It works as a counter-signal to FGFR3, the receptor that, when overactive, holds back the growth plates in the long bones.
- Increases growth velocity in achondroplasia
- Targets the actual FGFR3 mechanism, not a symptom
- Once-daily dosing
- First approved medicine for the condition
- Transient low blood pressure
- Dizziness
- Fatigue
Mechanism
Achondroplasia is driven by an overactive FGFR3 receptor, which brakes the cartilage growth plates that lengthen bone. Vosoritide binds a different receptor, natriuretic receptor B (NPR-B), and switches on a signaling cascade that pushes back against FGFR3 further down the line (it dampens the MAPK pathway FGFR3 uses) [1]. The net effect is that the growth plates can do their job again, so cartilage cells proliferate and mature more normally and the long bones grow at a healthier rate; in the phase 3 trial, once-daily injections meaningfully increased growth velocity in children over a year [1]. Natural CNP is destroyed almost instantly in the body, so vosoritide is engineered to last long enough to be useful while still clearing quickly.
receptor fingerprint
Natriuretic receptor B (NPR-B)agonist
FGFR3 / MAPK pathwayopposes (downstream)
Blood pressurelowers (transient)
Safetyrisks and cautions, not medical advice
Prescription pediatric drug given under specialist care. The most notable effects come from its mild blood-pressure-lowering (vasodilatory) action, so injection-site reactions and transient drops in blood pressure are watched for. It is not a general-purpose or adult performance compound.
History
Vosoritide is a modified analog of C-type natriuretic peptide (CNP) developed by BioMarin Pharmaceutical under the codename BMN-111, engineered for greater resistance to enzymatic degradation so it can counteract the overactive FGFR3 signaling that drives achondroplasia. BioMarin advanced it through pediatric trials targeting linear growth in children with achondroplasia, culminating in a pivotal placebo-controlled Phase III study showing increased annualized growth velocity.
It was first approved in the European Union in August 2021, and the FDA granted accelerated approval on November 19, 2021 under the trade name Voxzogo, making it the first approved drug specifically for achondroplasia. In October 2023 the FDA broadened the indication to include children under five with open growth plates. As the first pharmacologic therapy for the condition, its approval was closely followed, and debated, within the dwarfism community.
Subjective profileweighing the evidence above
A real advance for children with achondroplasia, because it pushes back on the FGFR3 signal causing the condition rather than working around it, and growth velocity measurably improves. Specialist pediatric medicine given by daily injection; it has nothing to offer adults or athletes.
Resources
This entry is here for reference.
Research
- 1.Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial
1 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
How can a peptide make bones grow?
It taps into your own growth-plate biology. By switching on the NPR-B receptor, it opposes the overactive FGFR3 signal that otherwise stalls the cartilage plates, letting the long bones lengthen closer to a normal pace.
Why does it have to be injected every day?
The natural peptide it copies is cleared from the blood in minutes. Even the engineered version is short-lived, so a daily dose keeps the signal going while the child's growth plates are still open.
Is this used in adults?
No; it works on open growth plates, so it is aimed at children who are still growing. Once the plates close, the mechanism no longer applies.
What is the main thing to watch for?
Because it nudges blood pressure down, the biggest practical concern is transient low blood pressure and injection-site reactions, which is why it is dosed and monitored carefully.
Adverse effects
- Transient low blood pressure
- Dizziness
- Fatigue
Notes and cautions
- Injection-site reactions